Quantcast

Global Continuous Glucose Monitoring (Guardian Real Time, FreeStyle Navigator, Dexcom Seven Plus, Dexcom G4 Platinum, MiniMed Paradigm Revel/Veo CGM Systems) Market – Forecast to 2019

May 22, 2014

DUBLIN, May 22, 2014 /PRNewswire/ – Research and Markets (http://www.researchandmarkets.com/research/wqkgq3/continuous) has announced the addition of the “Global Continuous Glucose Monitoring (Guardian Real Time, FreeStyle Navigator, Dexcom Seven Plus, Dexcom G4 Platinum, MiniMed Paradigm Revel/Veo CGM Systems) Market – Forecast to 2019″ report to their offering.

http://photos.prnewswire.com/prnh/20130307/600769



The rapid rise in diabetic population across the globe has considerably increased the demand for effective diabetes management systems. Currently, blood glucose meters are widely used for diabetes management; however, the trend is shifting towards minimally invasive (CGMS) or noninvasive glucose monitoring systems as these systems reduce the need for regular finger pricking and also lessen the pain. Continuous glucose monitoring systems are real time glucose sensing and monitoring devices that measure and display glucose levels of a patient at regular intervals.



The usage of CGM is substantially increasing over traditional glucose monitoring systems as these systems are user friendly, provide access to real time values and trend, and provide enhanced accuracy. Additionally, it has been observed that continuous glucose monitoring significantly helps in diabetes management especially in type I diabetics, and helps in reducing long-term complications associated with diabetes. Increasing awareness in developed and developing economies, technological advancements and rising number of diabetic patients are some of the key factors that are expected to fuel the growth of this market.



According to International Diabetes Federation (IDF) reports, approximately 382 million people globally were diagnosed with diabetes in 2013 and this number is expected to grow to 592 million by 2035. Additionally, as per Juvenile Diabetes Research Foundation (JDRF), the prevalence of type I diabetes rose by 23% in the U.S. between 2001 and 2009 for children under 20 years of age and is identified as the seventh leading cause of death in the country. Hence, rising number of patients suffering from type I diabetes is likely to increase the demand for CGMS.



The continuous glucose monitoring market has been segmented on the basis of various CGM systems available in the market including Guardian Real Time CGM System, FreeStyle Navigator, Dexcom Seven Plus, Dexcom G4 Platinum and MiniMed Paradigm Revel/Veo CGM Systems. In 2012, the market for Guardian Real Time CGM system held the largest share globally, followed by Dexcom Seven Plus CGM system. However, during the forecast period 2013 to 2019, growth of the market for Guardian Real Time CGM system is expected to be slowest due to market saturation and development of innovative competitor products.

Key Topics Covered:



Chapter 1 Preface



Chapter 2 Executive Summary



Chapter 3 Market Overview



Chapter 4 Continuous Glucose Monitoring (CGM) Market, by Device/Brand, 2011 – 2019 (USD Million)



Chapter 5 Global Continuous Glucose Monitoring Market Revenue, by Geography, 2011 – 2019 (USD Million)



Chapter 6 Competitive Landscape



Chapter 7 Recommendations



Chapter 8 Company Profiles



Companies Mentioned:

    --  Abbott Laboratories
    --  Bayer AG
    --  Dexcom, Inc.
    --  GlySens Incorporated
    --  Insulet Corporation
    --  Medtronic, Inc.
    --  Nova Biomedical Corporation
    --  Senseonics, Incorporated

For more information visit http://www.researchandmarkets.com/research/wqkgq3/continuous

Media Contact: Laura Wood, +353-1-481-1716, press@researchandmarkets.net

SOURCE Research and Markets


Source: PR Newswire



comments powered by Disqus